Research progress on the relationship of vitamin D and vitamin D receptor gene polymorphism with Parkinson’s disease_West China Medical Journal

Authors：

LIN Jing ,  LI Jie

Department of Neurology, Deyang People’s Hospital, Deyang, Sichuan 618000, P. R. China;

Corresponding author：

LI Jie, Email: lijie860114@163.com

Keywords：

Parkinson’s disease; vitamin D; vitamin D receptor; gene polymorphism

DOI：

10.7507/1002-0179.202303216

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Parkinson’s disease is a common chronic progressive neurodegenerative disease, and its main pathological change is the degeneration and loss of dopaminergic neurons in substantia nigra striatum. Vitamin D receptors are widely distributed in neurons and glial cells, and the normal function of substantia nigra striatum system depends on the level of vitamin D and the normal expression of vitamin D receptors. In recent years, from basic to clinical research, there are some differences in the conclusion of the correlation of vitamin D and its receptor gene polymorphism with Parkinson’s disease. This paper aims to review the research on the correlation of vitamin D and vitamin D receptor gene polymorphism with Parkinson’s disease, and discuss the future research direction in this field.

Citation： LIN Jing, LI Jie. Research progress on the relationship of vitamin D and vitamin D receptor gene polymorphism with Parkinson’s disease. West China Medical Journal, 2023, 38(5): 749-752. doi: 10.7507/1002-0179.202303216 Copy

1.	Panicker N, Ge P, Dawson VL, et al. The cell biology of Parkinson’s disease. J Cell Biol, 2021, 220(4): e202012095.
2.	Cui X, Pelekanos M, Liu PY, et al. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience, 2013, 236: 77-87.
3.	Lv L, Tan X, Peng X, et al. The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease. Transl Neurodegener, 2020, 9(1): 34.
4.	Baggerly CA, Cuomo RE, French CB, et al. Sunlight and vitamin D: necessary for public health. J Am Coll Nutr, 2015, 34(4): 359-365.
5.	Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat, 2005, 29(1): 21-30.
6.	Fullard ME, Duda JE. A review of the relationship between vitamin D and Parkinson disease symptoms. Front Neurol, 2020, 11: 454.
7.	da Costa RO, Gadelha-Filho CVJ, de Aquino PEA, et al. Vitamin D (VD₃) intensifies the effects of exercise and prevents alterations of behavior, brain oxidative stress, and neuroinflammation, in hemiparkinsonian rats. Neurochem Res, 2023, 48(1): 142-160.
8.	Suzuki M, Yoshioka M, Hashimoto M, et al. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease. Mov Disord, 2012, 27(2): 264-271.
9.	Knekt P, Kilkkinen A, Rissanen H, et al. Serum vitamin D and the risk of Parkinson disease. Arch Neurol, 2010, 67(7): 808-811.
10.	Rimmelzwaan LM, van Schoor NM, Lips P, et al. Systematic review of the relationship between vitamin D and Parkinson’s disease. J Parkinsons Dis, 2016, 6(1): 29-37.
11.	Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr, 2013, 97(5): 1004-1013.
12.	Sleeman I, Aspray T, Lawson R, et al. The role of vitamin D in disease progression in early Parkinson’s disease. J Parkinsons Dis, 2017, 7(4): 669-675.
13.	Zhang HJ, Zhang JR, Mao CJ, et al. Relationship between 25-hydroxyvitamin D, bone density, and Parkinson’s disease symptoms. Acta Neurol Scand, 2019, 140(4): 274-280.
14.	Shrestha S, Lutsey PL, Alonso A, et al. Serum 25-hydroxyvitamin D concentrations in mid-adulthood and Parkinson’s disease risk. Mov Disord, 2016, 31(7): 972-978.
15.	Larsson SC, Singleton AB, Nalls MA, et al. No clear support for a role for vitamin D in Parkinson’s disease: a mendelian randomization study. Mov Disord, 2017, 32(8): 1249-1252.
16.	Uitterlinden AG, Fang Y, Van Meurs JB, et al. Genetics and biology of vitamin D receptor polymorphisms. Gene, 2004, 338(2): 143-156.
17.	Burne TH, McGrath JJ, Eyles DW, et al. Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res, 2005, 157(2): 299-308.
18.	Bouillon R, Carmeliet G, Daci E, et al. Vitamin D metabolism and action. Osteoporos Int, 1998, 8(Suppl 2): S13-S19.
19.	Tanaka K, Miyake Y, Fukushima W, et al. Vitamin D receptor gene polymorphisms, smoking, and risk of sporadic Parkinson’s disease in Japan. Neurosci Lett, 2017, 643: 97-102.
20.	Kang SY, Park S, Oh E, et al. Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: revisited. Neurosci Lett, 2016, 628: 230-235.
21.	Han X, Xue L, Li Y, et al. Vitamin D receptor gene polymorphism and its association with Parkinson’s disease in Chinese han population. Neurosci Lett, 2012, 525(1): 29-33.
22.	张亚男. 维生素 D 受体基因多态性与特发性癫痫的相关性研究. 呼和浩特: 内蒙古医科大学, 2020.
23.	Lv Z, Tang B, Sun Q, et al. Association study between vitamin D receptor gene polymorphisms and patients with Parkinson disease in Chinese han population. Int J Neurosci, 2013, 123(1): 60-64.
24.	Gao J, Teng J, Liu Z, et al. Association between vitamin D receptor polymorphisms and susceptibility to Parkinson’s disease: an updated meta-analysis. Neurosci Lett, 2020, 720: 134778.
25.	Agliardi C, Guerini FR, Zanzottera M, et al. The VDR Fok I (rs2228570) polymorphism is involved in Parkinson’s disease. J Neurol Sci, 2021, 428: 117606.
26.	Redenšek S, Kristanc T, Blagus T, et al. Genetic variability of the vitamin D receptor affects susceptibility to Parkinson’s disease and dopaminergic treatment adverse events. Front Aging Neurosci, 2022, 14: 853277.
27.	Gatto NM, Paul KC, Sinsheimer JS, et al. Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson’s disease. J Neurol Sci, 2016, 370: 100-106.
28.	Gatto NM, Sinsheimer JS, Cockburn M, et al. Vitamin D receptor gene polymorphisms and Parkinson’s disease in a population with high ultraviolet radiation exposure. J Neurol Sci, 2015, 352(1/2): 88-93.
29.	Geng J, Zhang J, Yao F, et al. A systematic review and meta-analysis of the associations of vitamin D receptor genetic variants with two types of most common neurodegenerative disorders. Aging Clin Exp Res, 2020, 32(1): 21-27.

1. Panicker N, Ge P, Dawson VL, et al. The cell biology of Parkinson’s disease. J Cell Biol, 2021, 220(4): e202012095.
2. Cui X, Pelekanos M, Liu PY, et al. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience, 2013, 236: 77-87.
3. Lv L, Tan X, Peng X, et al. The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease. Transl Neurodegener, 2020, 9(1): 34.
4. Baggerly CA, Cuomo RE, French CB, et al. Sunlight and vitamin D: necessary for public health. J Am Coll Nutr, 2015, 34(4): 359-365.
5. Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat, 2005, 29(1): 21-30.
6. Fullard ME, Duda JE. A review of the relationship between vitamin D and Parkinson disease symptoms. Front Neurol, 2020, 11: 454.
7. da Costa RO, Gadelha-Filho CVJ, de Aquino PEA, et al. Vitamin D (VD₃) intensifies the effects of exercise and prevents alterations of behavior, brain oxidative stress, and neuroinflammation, in hemiparkinsonian rats. Neurochem Res, 2023, 48(1): 142-160.
8. Suzuki M, Yoshioka M, Hashimoto M, et al. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease. Mov Disord, 2012, 27(2): 264-271.
9. Knekt P, Kilkkinen A, Rissanen H, et al. Serum vitamin D and the risk of Parkinson disease. Arch Neurol, 2010, 67(7): 808-811.
10. Rimmelzwaan LM, van Schoor NM, Lips P, et al. Systematic review of the relationship between vitamin D and Parkinson’s disease. J Parkinsons Dis, 2016, 6(1): 29-37.
11. Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr, 2013, 97(5): 1004-1013.
12. Sleeman I, Aspray T, Lawson R, et al. The role of vitamin D in disease progression in early Parkinson’s disease. J Parkinsons Dis, 2017, 7(4): 669-675.
13. Zhang HJ, Zhang JR, Mao CJ, et al. Relationship between 25-hydroxyvitamin D, bone density, and Parkinson’s disease symptoms. Acta Neurol Scand, 2019, 140(4): 274-280.
14. Shrestha S, Lutsey PL, Alonso A, et al. Serum 25-hydroxyvitamin D concentrations in mid-adulthood and Parkinson’s disease risk. Mov Disord, 2016, 31(7): 972-978.
15. Larsson SC, Singleton AB, Nalls MA, et al. No clear support for a role for vitamin D in Parkinson’s disease: a mendelian randomization study. Mov Disord, 2017, 32(8): 1249-1252.
16. Uitterlinden AG, Fang Y, Van Meurs JB, et al. Genetics and biology of vitamin D receptor polymorphisms. Gene, 2004, 338(2): 143-156.
17. Burne TH, McGrath JJ, Eyles DW, et al. Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res, 2005, 157(2): 299-308.
18. Bouillon R, Carmeliet G, Daci E, et al. Vitamin D metabolism and action. Osteoporos Int, 1998, 8(Suppl 2): S13-S19.
19. Tanaka K, Miyake Y, Fukushima W, et al. Vitamin D receptor gene polymorphisms, smoking, and risk of sporadic Parkinson’s disease in Japan. Neurosci Lett, 2017, 643: 97-102.
20. Kang SY, Park S, Oh E, et al. Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: revisited. Neurosci Lett, 2016, 628: 230-235.
21. Han X, Xue L, Li Y, et al. Vitamin D receptor gene polymorphism and its association with Parkinson’s disease in Chinese han population. Neurosci Lett, 2012, 525(1): 29-33.
22. 张亚男. 维生素 D 受体基因多态性与特发性癫痫的相关性研究. 呼和浩特: 内蒙古医科大学, 2020.
23. Lv Z, Tang B, Sun Q, et al. Association study between vitamin D receptor gene polymorphisms and patients with Parkinson disease in Chinese han population. Int J Neurosci, 2013, 123(1): 60-64.
24. Gao J, Teng J, Liu Z, et al. Association between vitamin D receptor polymorphisms and susceptibility to Parkinson’s disease: an updated meta-analysis. Neurosci Lett, 2020, 720: 134778.
25. Agliardi C, Guerini FR, Zanzottera M, et al. The VDR Fok I (rs2228570) polymorphism is involved in Parkinson’s disease. J Neurol Sci, 2021, 428: 117606.
26. Redenšek S, Kristanc T, Blagus T, et al. Genetic variability of the vitamin D receptor affects susceptibility to Parkinson’s disease and dopaminergic treatment adverse events. Front Aging Neurosci, 2022, 14: 853277.
27. Gatto NM, Paul KC, Sinsheimer JS, et al. Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson’s disease. J Neurol Sci, 2016, 370: 100-106.
28. Gatto NM, Sinsheimer JS, Cockburn M, et al. Vitamin D receptor gene polymorphisms and Parkinson’s disease in a population with high ultraviolet radiation exposure. J Neurol Sci, 2015, 352(1/2): 88-93.
29. Geng J, Zhang J, Yao F, et al. A systematic review and meta-analysis of the associations of vitamin D receptor genetic variants with two types of most common neurodegenerative disorders. Aging Clin Exp Res, 2020, 32(1): 21-27.

Previous Article
Factors affecting the prognosis of immune-mediated necrotizing myopathy: a review
Next Article
Progress in basic research and clinical application of median nerve electrical stimulation

West China Medical Journal

Research progress on the relationship of vitamin D and vitamin D receptor gene polymorphism with Parkinson’s disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content